ByTrending Posts
AI-Powered Insilico Medicine Doses First Patient in Phase…
Cambridge, Mass. — Jan 22, 2025 Insilico Medicine, a biotechnology company leveraging generative artificial intelligence (AI) for drug…
Insilico Medicine’s AI Platform Unveils GBP2 and HCK…
InSilico Medicine — Jan 15, 2025AI-Driven Research Unveils New Therapeutic Approaches Researchers have leveraged artificial intelligence to discover…
Can Yseop and Novartis Cut Drug Development Timelines…
Elite AI Partnership with NovartisYseop has been named among only seven elite AI partners by Novartis, aiming to…
Dyno Therapeutics Reveals Roche’s Decision to Exercise Option…
January 13, 2025 Dyno Therapeutics has announced that Roche has exercised its option to license a novel AAV…
NVIDIA Joins Forces with Industry Leaders to Revolutionize…
J.P. Morgan Healthcare Conference — Jan 13, 2025 At the J.P. Morgan Healthcare Conference, NVIDIA unveiled transformative partnerships…
Insilico Medicine Identifies Novel Endometriosis Targets and Repurposes…
FLORENCE, Italy & CAMBRIDGE, Mass.— Jan 10, 2025AI-Driven Research Unveils New Therapeutic Approaches Researchers have leveraged artificial intelligence…
XtalPi and UCB Partner to Advance AI-Powered Biologic…
Cambridge, MA – Jan 10 2025 XtalPi Inc. (HKEX: 2228.HK), a leader in AI-powered pharmaceutical technology, announced a…
Can AI-Powered Drug Discovery Redefine Cardiometabolic Treatment? Novo…
Key Takeaways for Industry Leaders A Landmark Expansion: 20 Programs, $4.6 Billion, and a Bold Vision for AI…
Recursion Advances AI-Powered Oncology Pipeline with REC-3565 and…
Salt Lake City – January 7, 2025 Recursion, a clinical-stage TechBio company pioneering the integration of artificial intelligence…
Trending Posts
Latest Stories
How Did Novartis’ 2025 Deals Shape Its Strategic Direction and What Might They Signal for 2026?
Novartis’ deal activity in 2025 reflected a deliberate and strategic effort to strengthen its scientific…
How Did Novartis Navigate 2025 and What’s Ahead for 2026?
In 2025, Novartis demonstrated resilience and strategic focus, balancing strong performance in its core franchises…
How Did AbbVie’s 2025 Deals Shape Its Year, and What Do They Signal for Growth in 2026?
NORTH CHICAGO, IL — As 2025 concludes, AbbVie Inc. reflects on a year of strategic…
Did AbbVie Successfully Manage 2025 Headwinds, and Are Rinvoq and Skyrizi Poised to Reach $31B+ Sales by 2027?
NORTH CHICAGO, ILLINOIS — As 2025 comes to a close, AbbVie reflects on a year…
Gallery
